In agreement with previous studies [30], we showed that ERK–ZEB1 signaling promotes epithelial to mesenchymal transition in cancer cells, and treatment of CD44-overexpressing cells with ERK phosphorylation inhibitor PD98059 reversed ZEB1 and Claudin-1 expression levels. The gene discussed is CLDN1; the disease is cancer.